Court rules against Teva in generic harm case; FDA approves new use of Stelera; EC gives nod to Gilead's Tybost;

@FiercePharma: Top story yesterday online: If reps can't get in doctors' front doors, try alternate routes. Item | Follow @FiercePharma

@EricPFierce: Judge smokes jury's $1.7 million verdict against Takeda for not properly warning on Actos dangers. Article | Follow @EricPFierce

> The European Commission has approved use of Gilead Sciences' ($GILD) Tybost, a pharmacokinetic enhancer that boosts blood levels of certain HIV medicines. Release

> A federal appeals court in California has sided with plaintiffs against Teva Pharmaceutical Industries ($TEVA) in more cases trying to hold generic drugmakers accountable for alleged harm from ingredients that the reference drug requires. Story

> Florida Republican Representative Bill Young is asking FDA Commissioner Margaret Hamburg to evaluate whether some actions on drug pricing and gray market sales might help reduce drug shortages. Report

> The FDA has approved Janssen Biotech's Anti-IL-12/23 treatment Stelara (ustekinumab), alone or in combination with methotrexate, for the treatment of adult patients with active psoriatic arthritis. Release

Medical Device News

@FierceMedDev: axes jobs after FDA warns over pump. News | Follow @FierceMedDev

@MarkHFierce: KKR sealed the deal to buy Panasonic's healthcare business for $1.67B. Higher than expected. Press release | Follow @MarkHFierce

@MichaelGFierce: Laser-sensitive surface enables IV-drug identification for safer delivery. ICYMI from FierceDrugDelivery | Follow @MichaelGFierce

> Medtronic wins FDA nod to roll out auto-stop insulin device. Report

> Singulex grabs $55M in debt, equity for global in vitro diagnostics push. Article

Biotech News

@FierceBiotech: Popular yesterday: In another stinging setback, Eli Lilly's ramucirumab fails PhIII breast cancer study. Article | Follow @FierceBiotech

@JohnCFierce: ICYMI: Nektar Therapeutics shares crash on PhII pain drug trial flop. Story | Follow @JohnCFierce

@DamianFierce: After a so-so IPO, Regado is axing 15% of its employees, mostly in R&D. Article | Follow @DamianFierce

> ArQule rises on renewed hope for twice-damned tivantinib. More

> Third Rock's path to success lined with patience, rigor and T-shirts. Story

> Inotek snags $21M for PhII glaucoma drops. Item

> Yale biotech spinout launches with $18M and a new approach to cancer. Report

And Finally... GlaxoSmithKline ($GSK) will add 20 jobs to a plant in Cork, Ireland, as part of expansion there. Report